Endoscopic Sleeve Gastroplasty for Obesity: A multicenter French real-world study

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study collects real-world data from several French centers to evaluate the safety and effectiveness of Endoscopic Sleeve Gastroplasty in adults with BMI 30 or higher who are not eligible or do not wish to undergo bariatric surgery. It analyzes weight loss outcomes and related health effects over time, using routine clinical practice across sites. The trial emphasizes variability in ESG practice and outcomes across institutions in France. Results will inform clinical decision-making and patient selection in the French healthcare context.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged 18 to 75 years.
* Patients with a Body Mass Index (BMI) ≥ 30 kg/m².
* Patients who have failed non-surgical weight loss interventions (diet, exercise, pharmacological therapy).
* Patients not eligible for bariatric surgery or does not wish to undergo it.
* Patients who can undergo general anesthesia.
* Patients who are able to participate in all aspects of the study and agree to comply with all study requirements for the entire duration of the study.
* Patients who are able to fully understand the study and are willing to give their consent to participate in the study.
* Patients affiliated with the French social security system.

Exclusion Criteria:

* Patients with contraindications to endoscopic gastroplasty
* Patients with active peptic ulcer disease or significant gastroparesis
* Patients with a history of bariatric, gastric, or esophageal surgery.
* Patients who have started medication in the last 3 months that is known to cause weight gain.
* Patients with a history of uncontrolled, poorly controlled, or suspected eating disorders or psychiatric illness.
* Patients with unstable and precarious health, as determined and assessed by the investigator.
* Patients who are pregnant, breastfeeding, or of childbearing age and not using effective contraception.
* Patients who are currently excluded (as determined by a previous or ongoing study).
* Patients under judicial protection.
* Patients under guardianship, conservatorship or subject to any form of protective supervision

Where it's running

• Hôpital Privé de Provence
  Aix-en-Provence, France Recruiting
• Clinique de la Sauvegarde
  Lyon, France Recruiting
• Hospices Civils de Lyon - Hôpital Edourard HERRIOT
  Lyon, France Recruiting
• Polyclinique Sainte Thérèse
  Sète, France Recruiting
• Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil
  Strasbourg, France Recruiting
• Polyclinique de Franche-Comté
  Besançon, France Not yet recruiting

Study contacts

• Principal investigator: Silvana PERRETTA, MD-PhD — Hôpitaux Universitaires de Strasbourg
• Study coordinator: Armelle TAKEDA
• Email: armelle.takeda@ihu-strasbourg.eu
• Phone: 0033 390 413608

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.